CD8A and melanoma: We also showed the administration of rIL-33 suppressed the growth of established melanoma tumors by increased expansion, tumor infiltration, and improved effector function of antigen-specific CD8+ IFN-γ+ T cells directly and indirectly through activation of myeloid dendritic cells (mDCs) [40].